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Abstract
Background: Hyperglycemia in premature infants is associated with increased morbidity and mortality, but data on
long-term outcome are limited. We investigated the effects of neonatal hyperglycemia (blood glucose ≥ 10 mmol/l,
treated with insulin for ≥ 12 hours) on growth and neurobehavioral outcome at 2 years of age.
Methods: Retrospective follow-up study at 2 years of age among 859 infants ≤32 weeks of gestation admitted to
a tertiary neonatal center between January 2002 and December 2006. Thirty-three survivors treated with insulin for
hyperglycemia and 63 matched controls without hyperglycemia were evaluated at a corrected age of 2 years.
Outcome measures consisted of growth (weight, length, and head circumference) and neurological and
behavioural development.
Results: 66/859 (8%) infants ≤ 32 weeks of gestation developed hyperglycemia. Mortality during admission was
27/66 (41%) in the hyperglycemia group versus 62/793 (8%) in those without hyperglycemia (p < 0.001). Mortality
was higher in infants with hyperglycemia with a birth weight ≤1,000 gram (p = 0.005) and/or gestational age of
24-28 weeks (p = 0.009) than in control infants without hyperglycemia. Sepsis was more prominent in infants with
hyperglycemia and a birth weight of >1,000 gram (p = 0.002) and/or gestational age of 29-32 weeks (p = 0.009)
than in control infants without hyperglycemia. Growth at 2 years of age was similar, but neurological and
behavioural development was more frequently abnormal among those with neonatal hyperglycemia (p = 0.036
and 0.021 respectively).
Conclusions: Mortality was higher in very preterm infants with hyperglycemia treated with insulin during the
neonatal period. At 2 years of age survivors showed normal growth, but a higher incidence of neurological and
behavioural problems. Better strategies to manage hyperglycemia may improve outcome of very preterm infants.
Background
Hyperglycemia is a common problem in very preterm
infants. Among extremely low birth weight infants the
incidence of neonatal hyperglycemia is estimated to be
between 45% and 80% [1-3]. This is possibly an under-
estimation as 50% of the abnormalities in glucose levels
are not detected by standard intermittent sampling and
the incidence is also influenced by the use of different
definitions [4,5]. Accurate monitoring of blood glucose
levels is clinically important, because abnormalities in
glucose homeostasis can have serious short term
consequences. Hyperglycemia is associated with
increased mortality, which is significantly related to the
duration of the hyperglycemia [6,7]. A higher incidence
of retinopathy of prematurity and intraventricular
hemorrhage (IVH) grade 3 and 4 has also been reported
[7,8].
Prematurity is an important risk factor in the complex
pathogenesis of hyperglycemia. Insulin resistance devel-
ops due to a high circulating level of inflammatory mar-
kers, cytokines and catecholamines. Consequently,
glucose production in the liver is not inhibited. The
pancreas needs to produce insulin to compensate, but is
probably unable to do so due to immature beta-cells,
leading to relative insulin deficiency [7,9,10].* Correspondence: F.J.Walther@lumc.nl1Division of Neonatology, Department of Pediatrics, Leiden University
Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
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Since twenty-five years continuous insulin infusion is
used, nevertheless in many centers restriction of glucose
intake is still the first step in treatment of hyperglycemia
[5].
Comparison of these interventions has demonstrated
the efficacy of continuous insulin infusion in glucose
control. Infants treated with insulin had a higher glucose
intake, a higher weight gain, less sepsis and an increased
endogenous insulin production [11,12]. The benefit of
early elective insulin therapy in the prevention and
treatment of hyperglycemia has been demonstrated in
critically ill adults, but is questionable in premature
infants. Although early elective insulin therapy decreases
hyperglycemia, it significantly increases the incidence of
hypoglycemia and mortality by 28 days [13-15].
Whereas the short term effects of neonatal hypergly-
cemia in very preterm infants have been reported, less is
known about the effects of hyperglycemia on growth
and neurobehavioural outcome. The aim of this retro-
spective follow-up study was to determine the possible
effects of hyperglycemia on growth and neurobehavioral
development by comparing very preterm infants with
and without a history of neonatal hyperglycemia at the
corrected age of two years.
Methods
Study population
The study population consisted of 859 very preterm
infants (≤ 32 weeks) admitted to the Neonatal Intensive
Care Unit (NICU) of the Leiden University Medical
Center between January 2002 and December 2006. Neo-
natal data and data on growth and neurobehavioural
outcome at the corrected age of 2 years were collected
from the charts in the tertiary neonatal center and the
regional hospitals where these infants were regularly
seen for follow-up. The Medical Ethics Committee of
the Leiden University Medical Center did not require
approval of this study because it consisted of retrospec-
tive chart review, nor did the medical ethics committee
require written consent by the parents for their infant’s
information to be stored in the hospital database and
used for research.
Hyperglycemia was defined as at least 2 blood glucose
levels of ≥10.0 mmol/L (180 mg/dL) during a 12-hour
period. Insulin treatment was started at 0.05 U/kg/h
[14] when hyperglycemia persisted after these 12 hours,
despite reduction of glucose intake to 5-6 mg/kg/min.
The insulin dosage was tapered after blood glucose
levels dropped to <10 mmol/L. The cohort of exposed
infants consisted of all preterm infants with neonatal
hyperglycemia and the unexposed cohort was a matched
selection of preterm infants admitted during the same
timeframe, but without hyperglycemia (and without
short-lived hyperglycemia <12 hours) and insulin
therapy. The infants were matched by birth weight
(± 0.1 kg), gestational age (± 1 week), gender, and date
of admission (a period of ± 1 year was preferred). Each
exposed infant was matched to 2 unexposed controls.
The exclusion criteria for both exposed and unexposed
infants were major congenital anomalies and chromoso-
mal abnormalities. The study size was determined by
the number of exposed infants during the study period
and the availability of matches.
Data collection
Blood glucose levels were measured in whole blood
using the glucose oxidase method. (Siemens RapidPoint
400/405 system, Siemens Healthcare Diagnostics B.V.,
Breda, The Netherlands). Frequency of glucose level
measurements was based on clinical and laboratory find-
ings. During the first week after birth blood glucose
levels were measured at least 6 times a day, thereafter
glucose levels were measured at least 3 times a day. In
the acute phase of hyperglycemia, glucose levels were
measured regularly with intervals of approximately 1-2
hours.
Data for demographic and perinatal characteristics as
well as postnatal clinical conditions of all infants were
collected from the charts and included birth weight,
gestational age, length of stay (as an indicator of severity
of illness), gender, exposure to prenatal and postnatal
steroids, presence of chorioamnionitis, sepsis, prolonged
rupture of membranes (PROM), respiratory distress syn-
drome (RDS) [16], bronchopulmonary dysplasia (BPD)
[17], necrotizing enterocolitis (NEC) [18], cystic periven-
tricular leukomalacia (PVL) [19] and intraventricular
hemorrhage (IVH) [20,21].
For the exposed infants the mean, minimum and max-
imum glucose levels, glucose intake and insulin infusion
rate were calculated for the first 5 days after the onset
of the hyperglycemia episode or until the end of the
hyperglycemia episode if the episode lasted longer than
5 days. Additionally, duration of hyperglycemia, fre-
quency of hypoglycemic periods, duration of insulin
infusion, mean serum sodium concentration, maximum
daily percentage of inhaled oxygen and maximum infu-
sion rate of inotropic drugs (dobutamine and dopa-
mine), were recorded.
Outcome data collected at the corrected age of 2 years
(± 3 months) included weight (kg), length (cm), head
circumference (cm), and neurobehavioral development.
Neurological outcome was classified into 3 groups: nor-
mal, mildly abnormal (detectable but not disabling
abnormalities of tone and reflexes, presence of abnormal
movements or asymmetry) and severely abnormal (dis-
abling abnormalities) according to the neurological
examination by Hempel [22]. Behavioural outcome was
scored normal or inadequate based on the Child
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Behavior Checklist/2-3 (CBCL/2-3) [23] completed by
the parents or orally by the clinic pediatrician.
Statistical analysis
Data are reported as mean values ± standard deviation,
numerical values or categories. Statistical analyses were
performed with SPSS Version 16.0 (SPSS Inc., Chicago,
IL). Numerical growth parameters were analyzed with
an unpaired T-test. The categorical data for behavioural
and neurological outcome were analyzed using a chi-
squared test.
Subgroup analyses were performed for subgroups in
gestational age (24-28 and 29-32 weeks) and birth
weight (≤1,000 gram and >1,000 gram).
Potential confounders in this study were gestational
age, gender, birth weight, length of stay, exposure to
prenatal and postnatal steroids, presence of severe RDS,
sepsis, PROM, chorioamnionitis, NEC, BPD, PVL and
IVH. Confounding was prevented by matching and
using multivariable regression analysis for analyzing
mortality and morbidity, as well as growth, neurological
and behavioural development. Infants with missing base-
line characteristics were excluded from regression
analyses.
Results
Between January 2002 and December 2006 a total of 859
very preterm infants with a gestational age less than 33
weeks were admitted for neonatal intensive care. Mean
gestational age was 29.4 ± 2.0 weeks and birth weight
1,323 ± 410 gram. Fifty-six percent was male. Prenatal
steroids were administered to 63% of the mothers. Chor-
ioamnionitis and PROM were present in 13 and 27%
respectively. Twenty-nine percent of the infants devel-
oped sepsis, 6% IVH grade 3 or 4, 3% cystic PVL, 2%
NEC grade 2 or 3, 19% RDS grade 3 or 4 and 14% BPD at
36 weeks postmenstrual age. Postnatal steroids were
administered to 10% of the infants. Hyperglycemia
occurred in 66 (8%) infants of whom 53 had a birth
weight of ≤1,000 gram, the incidence in this subgroup
was 25%. The mean age at onset of the hyperglycemia
episode was 3.2 ± 3.7 days. Twenty-seven out of 66
infants with hyperglycemia (41%) died during admission
versus 62/793 (8%) infants without hyperglycemia. Six of
the remaining 39 infants with hyperglycemia were
excluded from this follow-up study because of major
congenital anomalies (1) and loss to follow-up (5). Emi-
gration (1), placement in an unknown foster home (1)
and no appearance at follow-up appointments (3) were
the reasons for the loss to follow-up. These infants were
excluded from the analysis together with their unexposed
matches. For 3 exposed infants only 1 unexposed match
was available. The complete follow-up population con-
sisted of 96 infants; a flowchart can be seen in figure 1.
An overview of the baseline characteristics of included
patients is given in table 1. The exposed group had a
significantly longer length of stay than the unexposed
group, reason why statistical correction for confounders
by regression analysis was done.
Table 2 shows growth and development at 2 years of
corrected age. Weight, length, head circumference were
not different in the exposed cohort compared to the
unexposed cohort. The incidence of an abnormal neuro-
logical and behavioural outcome was higher in the
exposed group (p = 0.036 and 0.021 respectively).
Analyses of the data on the hyperglycemia episodes
(table 3) showed some significant relations. Mean and
maximum glucose levels on the third and fourth day of
the hyperglycemia episode correlated with mortality
(mean: p = 0.046, maximum: p = 0.041). Infants with a
mean glucose level > 8.0 mmol/L (144 mg/L) or a maxi-
mum glucose level > 9.5 mmol/L (171 mg/L) on the
third and fourth day had a higher mortality rate (p =
0.042 and p = 0.030, respectively). All hypoglycemia epi-
sodes were brief events which were corrected quickly.
Neurobehavioural outcome, growth or mortality were
not influenced by the frequency of hypoglycemia periods
and the duration of the hyperglycemia episode and cor-
rection for these potential confounders was therefore
not necessary.
A multivariable regression analysis on all very preterm
infants admitted between January 2002 and December
2006 (n = 798 infants with complete baseline character-
istics), confirmed a significant increase in mortality in
the exposed cohort (p = 0.001) (Table 4). Subgroup ana-
lysis demonstrated that infants with a birth weight ≤
1,000 gram (mean gestational age 27.3 ± 1.8 weeks)
and/or a gestational age of 24-28 weeks (mean birth
weight 972 ± 229 gram) also had a significant relation
between hyperglycemia and mortality.
In the subgroup of infants with a birth weight >1,000
gram (mean gestational age 30.1 ± 1.6 weeks) hypergly-
cemia was associated with an increased incidence of
IVH (p = 0.025), severe RDS (p = 0.012) and sepsis (p =
0.002). Sepsis was also more prominent in a subgroup
of infants with a gestational age of 29-32 weeks (p =
0.009, mean birth weight 1,503 ± 362 gram). In the
regression analyses for morbidity and mortality statisti-
cal correction was done for gestational age, gender,
birth weight, exposure to prenatal and postnatal ster-
oids, presence of severe RDS, sepsis, PROM, chorioam-
nionitis, NEC, BPD, PVL and IVH.
Discussion
The findings in this study indicate that hyperglycemia
has no effect on long term growth. However, in addition
to the already known short term effects, hyperglycemia
has a distinct negative influence on neurological and
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behavioural outcome at 2 years of age. The observation
by other investigators that hyperglycemia is a risk factor
for early mortality in very preterm infants was con-
firmed. We found a firm association between neonatal
mortality and the mean and maximum glucose levels on
days 3 and 4 of the hyperglycemia episode. This associa-
tion suggests that increased mortality is probably due to
poorly controlled hyperglycemia. No association
between mortality and duration of hyperglycemia was
found. In subgroup-analyses we found relations between
hyperglycemia and morbidity. Sepsis, severe RDS and
IVH were more common in infants with hyperglycemia
and a birth weight of >1,000 gram (mean gestational age
30.1 ± 1.6 weeks).
Hays et al. demonstrated that blood glucose concen-
tration had significant effects on both early death and
the occurrence of severe IVH [7]. To our knowledge,
adverse neurological and behavioural outcome second-
ary to neonatal hyperglycemia has not been reported yet.
This retrospective study has several limitations. An
observer-bias cannot be excluded because several physi-
cians did the follow-up consults at the age of 2 year. To
Figure 1 Flow chart of included patients.
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reduce the observer-bias as much as possible strict cut
off points were made and the follow-up information was
interpreted by only one person. In the future it would
be interesting to do a prospective study, in which Bayley
scores will be collected from all participants. Further-
more, it was quite difficult to match unexposed controls
for date of admission within 1 year to reduce the influ-
ence of changing policies. The composition of the unex-
posed control group was randomly chosen and purely
based on the in advance defined matching criteria.
Nonetheless, unintentional selection cannot be excluded
and the matched controls may not 100% represent the
complete population of very preterm infants admitted to
the nursery during the study period. An inevitable com-
plicating factor in this study was the concomitant occur-
rence of hyperglycemia and insulin therapy, through
which the individual influence of hyperglycemia or insu-
lin therapy cannot be demonstrated. Although this study
does not have the strength of a prospective follow-up
study, the results will give some support and direction
for the prognosis of the development of very preterm
infants with hyperglycemia.
Treatment with insulin is not unequivocally associated
with better outcome. The first study in adults by van
den Berghe showed very promising results [15]. How-
ever, it proved to be difficult to repeat the positive
Table 1 Baseline characteristics of very preterm infants included in the follow-up study.
Demographic and perinatal data Exposed (n = 33) Unexposed (n = 63) p-value
Gestational age (weeks) 28.2 ± 2.2 28.2 ± 2.2 1.000
Birth weight (grams) 962 ± 316 1008 ± 292 0.478
Length of stay (days) 47.2 ± 32.5 25.7 ± 45.1 0.017
Gender (male) 21 (64%) 39 (62%) 1.000
Prenatal steroids 0.721
0 doses 12 (36%) 22 (35%)
1 dose 13 (39%) 21 (33%)
>1 dose 8 (24%) 20 (32%)
Chorioamnionitis* 2 (6%) 6 (10%) 0.711
PROM** 9 (27%) 14 (22%) 0.620
Postnatal clinical conditions:
Sepsis*** 21 (64%) 37 (59%) 0.667
IVH grade 3/4 3 (9%) 3 (5%) 0.411
RDS grade 3/4 11 (33%) 19 (30%) 0.818
Cystic PVL 0 (0%) 2 (3%) 0.544
NEC grade 2/3 1 (3%) 0 (0%) 0.334
BPD **** 20 (61%) 25 (40%) 0.056
Postnatal steroid exposure 10 (30%) 13 (21%) 0.321
* Chorioamnionitis was defined as smelly amniotic fluid, maternal fever or signs of infection at birth.
** PROM was defined as rupture of membranes >24 hours.
*** Sepsis was defined as a positive blood culture.
**** Need for oxygen-therapy at a gestational age of 36 weeks or at discharge
Table 2 Growth and development at 2 years of corrected age.
Growth and outcome measures Exposed (n = 33) Unexposed (n = 63) p-value
Head circumference (cm) 47.8 ± 1.9 48.0 ± 1.8 0.613
Length (cm) 85.7 ± 4.0 85.0 ± 3.9 0.410
Weight (kg) 11.0 ± 1.5 11.0 ± 1.3 1.000
Neurological outcome 0.036
Normal 16 (48%) 47 (75%)
Mildly abnormal 12 (36%) 12 (19%)
Severely abnormal 5 (15%) 4 (6%)
Behavioural outcome 0.021
Normal 17 (52%) 48 (76%)
Inadequate 16 (48%) 15 (24%)
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results in later studies in adults, and some studies even
showed negative effects. Early treatment with insulin in
preterm infants (without hyperglycemia) even showed
higher mortality at 28 days in the early-insulin group
than in the control group [14]. The less favourable out-
come in the insulin-treated group in this study could
therefore also be due to the insulin therapy.
Several follow-up studies in infants with diabetes mel-
litus type 1 may explain our findings concerning neuro-
behavioural outcome. Infants with longer episodes of
hyperglycemia seem to have an impaired cognitive
development, though the specific impaired elements of
cognitive development vary between the studies. Com-
pared with healthy siblings, infants with hyperglycemia
had a lower verbal intelligence [24]. A follow-up study
conducted 2 years after the onset of type 1 diabetes sug-
gests that hyperglycemia is associated with compromised
learning- and consolidation capacities and organizational
strategies. However, this follow-up study was repeated
after another 4 years, at which time this relationship
could not be confirmed [25,26].
Conclusions
The results of this retrospective follow-up study suggest
that hyperglycemia and insulin therapy are not only
associated with increased mortality and short term
morbidity, but also exert long term effects on develop-
ment. Given the definition of hyperglycaemia, including
the use of insulin for >12 hours, one can not assume
that the association is due to poorly controlled hypergly-
cemia in this design, but may be the effect of insulin.
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